Partners

InhibOx maintains important partnerships with several organisations and research groups.

Commercial Partners

MolPort

MolPort is a rare chemical compound marketplace enabling worry free centralized ordering of chemicals from over 200 companies. To make the marketplace work MolPort has created a world class database of commercially available chemical compounds. The free access online search portal  www.molport.com  features unmatched advanced chemical structure search capabilities that are especially suited for a sophisticated and demanding user.

Through its alliance with MolPort, InhibOx provides a vertically integrated solution, providing physical screening samples of compounds identified by its computational technology

Intelligensys

Intelligensys enables companies involved in product formulation and process development to realize business potential, by providing software that unlocks the value in their existing experimental data.

Intelligensys was founded in 1999, building on activities pioneered within ICI PLC, Zeneca PLC, and Oxford Materials Ltd.  The core applications of Intelligensys artificial intelligence technology focused initially on product formulation. Since then, Intelligensys has grown to encompass selected areas of simulation to Pharma, Chemical, Coatings and Academic sectors. It has a worldwide customer base.

InhibOx is collaborating with Intelligensys to develop new applications of its technology to drug discovery, in particular virtual screening and the prediction of physicochemical properties.

Academic Collaborative networks

DeZnIT

DeZnIT is a European Union FP6 funded consortium.  The partners in DeZnIT are:

• InhibOx Ltd, UK
• Biochemical Institute, University of Kiel, Germany
• University of Naples, Italy
• Latvian Institute of Organic Synthesis, Latvia
• University of Tampere, Finland
• University of Florence, Italy
• University of Oxford, UK 

The goal of DeZnIT is to develop and apply new methodology for the rational and accelerated design of novel drugs targeted against zinc-containing enzymes. These enzymes are key modulators of many serious human diseases including cancer, glaucoma, obesity, and rheumatoid arthritis. Despite some successes, many major technological challenges remain in the development of effective drug therapies against this enzyme family.

DeZnIT is addressing these challenges by developing and integrating key technologies from pharmacogenomics, computer modelling, structural and molecular biology and chemistry, combined with drug discovery infrastructure and expertise.

The Role of InhibOx in the DeZniT consortium is to develop new methods for prediciting the activity of inhibitors of zinc enzymes and, together with its consortium partners, to identify new lead compounds for drug development.

STARS: Scientific Training in Antimicrobial Research Strategies

The Scientific Training in Antimicrobial Research Strategies, or STARS, is a European Initial Training Network Funded under the Marie Curie Actions of the Seventh Framework Programme for Early Stage Researchers who wish to undertake post-graduate training in antimicrobial research and development.

There is a growing problem of antimicrobial resistance, and thus an urgent need to redress the balance between this emerging drug resistance and currently available antimicrobial and anti-infective therapeutic options.  STARS has two sub-programmes on emerging drug targets, one found in a group of pathogenic Gram-positive bacteria, and the other focussing on the malaria parasite.

The partners in STARS are:

• InhibOx Ltd, UK
• Medical Research Council, National Institute for Medical Research, UK
  
• Ferrer Group, Spain
  
• Spanish National Research Council, Instituto de Biomedicina de Valencia, Spain
• Spanish National Research Council, Centro de Investigaciones Biológicas, Spain
• Latvian Institute of Organic Synthesis, Latvia
  
• Wageningen University, Host Microbe Interactomics, The Netherlands (Co-ordinator)
• Biaqualis, The Netherlands (Associated Partner)
• University of Siena, Italy
  

InhibOx is contributing through developing novel drug design technology and applying these methodologies to the drug targets of interest to the network.

University of Oxford SABS-DTC

InhibOx is a founder member of the Systems Approaches to Biomedical Science Industrial Doctorate Centre, or SABS-IDC, an industrial doctoral training centre run by the University of Oxford. The Oxford Industrial Doctorate Centre  provides a comprehensive training programme to graduates from mathematics, engineering, the physical and life sciences who wish to undertake research careers at the industrial interface in this exciting new inter-disciplinary field.

InhibOx contributes to the teaching component of this programme, and benefits from the interaction with excellent students and staff within the programme and wider departmental network.